65,437 trials
Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Proportion of Participants Alive and Without Progression — .66 proportion of participants
Mild Cognitive Impairment
Primary: Cognitive Scores at Baseline and Week 12 — 96; 99; 101; 103 score on a scale
Atropine Bioequivalence
Primary: The Bioequivalence of Atropine Sulfate Administered SL Versus Administered IM as Measured by Area Under the Analyte Concentration Versus Time Curve to Infinity (AUCinf)…
Treatment-Resistant Depression
Primary: Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score 24 Hours (Day 2) After Injection — -14.1; -11.4; -8.4; -8.9 Scores on a Scale
Type 2 Diabetes · PreDiabetes
Primary: Body Mass Index (BMI) - Post-Test — 30.3; 28.8 kg/m2
Wiskott-Aldrich Syndrome (WAS)
Primary: Safety of Reduced Conditioning Regimen — 8 Participants
Plaque Psoriasis
Primary: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 — 13.6; 6.8; 21.7; 17 percentage of…
Cerebral Palsy
Primary: Change in Preferred Walking Speed — 0.09; 0.13 m/s
Healthy
Primary: Percentage Change in the Time to Complete the Nine-hole Peg Test (9-HPT) to Immediate Post-intervention — 7.37; -0.15; -4.68 Percentage change in 9HPT time
Generalized Anxiety Disorder
Primary: Feasibility of Participant Recruitment and Intervention Delivery — 8; 8 months
Alcohol Drinking · Social Acceptance · Depressive Symptoms
Primary: Mean Value of Acceptability of Intervention Measure — 3.93 score on a scale — p=0.074
Motion Sickness
Primary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 11; 19; 40 Participants
Surgery--Complications
Primary: Overall Handoff Effectiveness — 3.9; 3.9; 4.0 score on a 0-5 scale — p=0.524
Alzheimer Disease · Dementia of Alzheimer Type
Primary: Global Statistical Test (GST) Score — -0.126; -0.208 Z-score
Renal Impairment
Primary: Maximum Serum Concentration (Cmax) of HM15912 — 2811.25; 3000.00 ng/mL